journal article·2023-11Open access

Improved Humoral Immunity and Protection against Influenza Virus Infection with a 3d Porous Biomaterial Vaccine

Hiromi Miwa, Olivia Q. Antao, Kindra M. Kelly‐Scumpia, Sevana Baghdasarian, Daniel P. Mayer, Lily Shang, Gina M. Sanchez, Maani M. Archang, Philip O. Scumpia, Jason S Weinstein, Dino Di Carlo

Advanced Science· Volume 10· Issue 31

Abstract

Abstract New vaccine platforms that activate humoral immunity and generate neutralizing antibodies are required to combat emerging pathogens, including influenza virus. A slurry of antigen‐loaded hydrogel microparticles that anneal to form a porous scaffold with high surface area for antigen uptake by infiltrating immune cells as the biomaterial degrades is demonstrated to enhance humoral immunity. Antigen‐loaded‐microgels elicited a robust cellular humoral immune response, with increased CD4 + T follicular helper (Tfh) cells and prolonged germinal center (GC) B cells comparable to the commonly used adjuvant, aluminum hydroxide (Alum). Increasing the weight fraction of polymer material led to increased material stiffness and antigen‐specific antibody titers superior to Alum. Vaccinating mice with inactivated influenza virus loaded into this more highly cross‐linked formulation elicited a strong antibody response and provided protection against a high dose viral challenge. By tuning physical and chemical properties, adjuvanticity can be enhanced leading to humoral immunity and protection against a pathogen, leveraging two different types of antigenic material: individual protein antigen and inactivated virus. The flexibility of the platform may enable design of new vaccines to enhance innate and adaptive immune cell programming to generate and tune high affinity antibodies, a promising approach to generate long‐lasting immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Respiratory viral infections research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering University of California Los Angeles Los Angeles CA 90095 USA

Center for Immunity and Inflammation Rutgers New Jersey Medical School Newark NJ 07103 USA

Division of Cardiology Department of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles CA 90095 USA

MSTP Program David Geffen School of Medicine University of California Los Angeles Los Angeles CA 90095 USA

Division of Dermatology Department of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles CA 90095 USA

Department of Dermatology VA Greater Los Angeles Healthcare System Los Angeles CA 90073 USA

Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles CA 90095 USA

Department of Mechanical and Aerospace Engineering University of California Los Angeles Los Angeles CA 90095 USA

California Nano Systems Institute (CNSI) University of California Los Angeles Los Angeles CA 90095 USA

Funding

W. M. Keck Foundation · National Institute of Allergy and Infectious Diseases · Office of Naval Research · National Institute of Arthritis and Musculoskeletal and Skin Diseases · National Institutes of Health · LEO Fondet

References (61)

Show source-provided references
1. 10.1016/j.immuni.2019.08.00710.1016/j.immuni.2019.08.007 ↗
2. Saleh A. · Cureus · 2021 · 13
3. 10.1089/vim.2017.014110.1089/vim.2017.0141 ↗
4. 10.3390/vaccines602001910.3390/vaccines6020019 ↗
5. 10.1016/j.immuni.2005.12.00510.1016/j.immuni.2005.12.005 ↗
6. 10.1016/j.vaccine.2010.03.06710.1016/j.vaccine.2010.03.067 ↗
7. 10.1016/j.vaccine.2016.11.01310.1016/j.vaccine.2016.11.013 ↗
8. 10.1093/infdis/jix63210.1093/infdis/jix632 ↗
9. 10.1084/jem.2012099410.1084/jem.20120994 ↗
10. 10.1126/sciimmunol.aam916910.1126/sciimmunol.aam9169 ↗
11. 10.1016/j.immuni.2011.03.02310.1016/j.immuni.2011.03.023 ↗
12. Shiloh Y. · Am. J. Hum. Genet. · 1990 · 47 · 20
13. 10.1038/s41586-022-05216-910.1038/s41586-022-05216-9 ↗
14. 10.1073/pnas.160605011310.1073/pnas.1606050113 ↗
15. 10.1002/eji.20083854910.1002/eji.200838549 ↗
16. 10.4049/jimmunol.181.1.1710.4049/jimmunol.181.1.17 ↗
17. 10.1038/s41563-022-01251-z10.1038/s41563-022-01251-z ↗
18. 10.1126/sciimmunol.abf115210.1126/sciimmunol.abf1152 ↗
19. 10.1016/j.biomaterials.2021.12115910.1016/j.biomaterials.2021.121159 ↗
20. 10.1039/D2BM00011C10.1039/D2BM00011C ↗
21. 10.1016/j.ijpharm.2016.11.04810.1016/j.ijpharm.2016.11.048 ↗
22. 10.1126/sciadv.aay773510.1126/sciadv.aay7735 ↗
23. Butenko S. · Cold Spring Harb. Perspect. Biol. · 2022 · 1510.1101/cshperspect.a041242 ↗
24. 10.1111/imcb.1203110.1111/imcb.12031 ↗
25. 10.1038/s41467-021-23482-510.1038/s41467-021-23482-5 ↗
26. 10.1126/sciadv.abb847110.1126/sciadv.abb8471 ↗
27. 10.1016/j.actbio.2021.04.02110.1016/j.actbio.2021.04.021 ↗
28. 10.1038/s41563-020-00844-w10.1038/s41563-020-00844-w ↗
29. 10.1016/j.jid.2019.01.03710.1016/j.jid.2019.01.037 ↗
30. 10.1016/j.actbio.2012.05.00610.1016/j.actbio.2012.05.006 ↗
31. 10.7554/eLife.5599510.7554/eLife.55995 ↗
32. 10.1002/adhm.20210137010.1002/adhm.202101370 ↗
33. 10.3389/fimmu.2020.0154710.3389/fimmu.2020.01547 ↗
34. 10.1038/s41551-021-00756-310.1038/s41551-021-00756-3 ↗
35. 10.1038/nmat429410.1038/nmat4294 ↗
36. 10.1002/smll.20190314710.1002/smll.201903147 ↗
37. 10.1002/adfm.20217025910.1002/adfm.202170259 ↗
38. 10.1016/j.actbio.2022.05.04910.1016/j.actbio.2022.05.049 ↗
39. 10.1002/adfm.20200430710.1002/adfm.202004307 ↗
40. 10.1038/nmat429010.1038/nmat4290 ↗
41. 10.1126/sciadv.abj583010.1126/sciadv.abj5830 ↗
42. 10.1002/advs.20220488210.1002/advs.202204882 ↗
43. 10.1038/s41434-018-0040-910.1038/s41434-018-0040-9 ↗
44. 10.1002/mabi.20180024210.1002/mabi.201800242 ↗
45. 10.1038/s41563-018-0028-210.1038/s41563-018-0028-2 ↗
46. 10.1016/j.jconrel.2016.05.03310.1016/j.jconrel.2016.05.033 ↗
47. 10.1021/acsnano.8b0024210.1021/acsnano.8b00242 ↗
48. 10.1084/jem.172.6.168110.1084/jem.172.6.1681 ↗
49. 10.1016/S0264-410X(96)00073-410.1016/S0264-410X(96)00073-4 ↗
50. 10.1016/j.vaccine.2011.09.12410.1016/j.vaccine.2011.09.124 ↗
51. 10.4049/jimmunol.090016410.4049/jimmunol.0900164 ↗
52. 10.1084/jem.178.4.129310.1084/jem.178.4.1293 ↗
53. 10.1002/j.1460-2075.1988.tb03038.x10.1002/j.1460-2075.1988.tb03038.x ↗
54. 10.4049/jimmunol.080077110.4049/jimmunol.0800771 ↗
55. 10.1038/s41577-022-00761-w10.1038/s41577-022-00761-w ↗
56. 10.1002/jbm.a.3213410.1002/jbm.a.32134 ↗
57. 10.3389/fimmu.2018.0222410.3389/fimmu.2018.02224 ↗
58. 10.1080/14760584.2016.118800910.1080/14760584.2016.1188009 ↗
59. 10.1088/1361-648X/ac655910.1088/1361-648X/ac6559 ↗
60. 10.2174/156802661866618011815451410.2174/1568026618666180118154514 ↗
61. 10.1016/j.matt.2020.03.01810.1016/j.matt.2020.03.018 ↗